13D Filing: James E. Flynn and Proteon Therapeutics Inc (PRTO)

Page 14 of 20

Page 14 of 20 – SEC Filing

Page 13 of 21

(3) Deerfield Mgmt III

Number of
Shares: 877,799

Percentage
of Shares: 4.98%

(4) Deerfield Partners

Number of shares: 86,867

Percentage of shares: 0.49%

(5) Deerfield Special Situations
Fund

Number of shares: 149,676

Percentage of shares: 0.85%

(6) Deerfield International Master
Fund

Number of
Shares: 110,557

Percentage
of Shares: 0.63%

(7) Deerfield Private Design
Fund III

Number of
Shares: 877,799

Percentage
of Shares: 4.98%

(8) Deerfield Private Design
Fund IV

Number of
Shares: 16,082,018

Percentage
of Shares: 9.985%

(9) Deerfield Mgmt IV

Number of
Shares: 16,082,018

Percentage
of Shares: 9.985%

(10) Flynn

Number of shares: 17,306,917

Percentage of shares: 9.985%

(b)

(1) Deerfield Management

Sole power to vote or direct the
vote: 0

Shared power to vote or direct
the vote: 17,306,917

Sole power to dispose or to direct
the disposition: 0

Shared power to dispose or direct
the disposition: 17,306,917

Follow Protara Therapeutics Inc. (NASDAQ:TARA)

Page 14 of 20